AlphaQuest LLC Has $333,000 Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

AlphaQuest LLC increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 49,687.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,983 shares of the biopharmaceutical company’s stock after purchasing an additional 3,975 shares during the quarter. AlphaQuest LLC’s holdings in Intra-Cellular Therapies were worth $333,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Wasatch Advisors LP lifted its holdings in shares of Intra-Cellular Therapies by 3.5% during the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock worth $281,601,000 after acquiring an additional 130,351 shares during the period. Bellevue Group AG raised its position in Intra-Cellular Therapies by 0.6% in the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock worth $181,873,000 after purchasing an additional 14,342 shares in the last quarter. State Street Corp lifted its stake in Intra-Cellular Therapies by 3.1% during the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock worth $136,017,000 after purchasing an additional 56,664 shares during the period. Franklin Resources Inc. boosted its holdings in Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after purchasing an additional 155,655 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Intra-Cellular Therapies by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company’s stock valued at $125,029,000 after purchasing an additional 22,128 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI opened at $131.26 on Friday. The stock has a market capitalization of $13.96 billion, a P/E ratio of -150.87 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52 week low of $63.87 and a 52 week high of $131.40. The stock has a fifty day moving average of $123.95 and a 200-day moving average of $95.39.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Equities research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ITCI shares. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.